Offer Request Form

Order list is empty

Shikari® (Q-MEP) Mepolizumab ELISA
Enzyme immunoassay for the quantitative determination of Mepolizumab (Nucala®) in human serum and plasma

This kit has been especially developed for the quantitative determination of Mepolizumab in serum and plasma samples between the Cmin and Cmax range of concentrations. Mepolizumab Drug Bank Accession Number is DB06612.

Mepolizumab is an anti-IL-5 IgG1 kappa monoclonal antibody indicated as an add-on maintenance treatment in patients aged six years and older with severe eosinophilic asthma and as a treatment in adult patients for eosinophilic granulomatosis with polyangiitis (EGPA). Mepolizumab is also indicated for the treatment of hypereosinophilic syndrome (HES) in patients aged 12 and older in whom eosinophilia is present for at least six months without an identifiable nonhematologic secondary cause.

All SHIKARI® ELISA kits are suitable for biosimilar work.

All SHIKARI® ELISA kits are produced under ISO 13485 quality system.

Research Use Only (RUO)

For technical inquiry, IFU and other relevant documents please contact techsupport@matriksbiotek.com

Required Volume (µl) 5
Total Time (min) 70
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) 20
Spike Recovery (%) Between 85-115
Shelf Life (month) 6
Assay type Quantitative
Species Reactivity Human
Storage conditions Store at +4°C. Please refer to protocols.
Shipping conditions At room temperature
# File Action
SDS Download

Publications with this drug

# File Action